Novo Nordisk A/S

Copenhagen Stock Exchange:NOVO-B.CO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Denmark

Market Cap

USD 356.43 B

Share Price

USD 79.75

Avg Daily Volume

5,846,065

Change (1 day)

-0.88%

Change (1 year)

-43.36%

Change (YTD)

-8.15%

Novo Nordisk A/S Price to Earnings Ratio (P/E) on June 13, 2025: 25.50

Novo Nordisk A/S Price to Earnings Ratio (P/E) is 25.50 on June 13, 2025, a -49.57% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Novo Nordisk A/S 52-week low Price to Earnings Ratio (P/E) is 52.94 on June 13, 2025, which is 107.58% above the current Price to Earnings Ratio (P/E).
Novo Nordisk A/S 52-week low Price to Earnings Ratio (P/E) is 18.85 on June 13, 2025, which is -26.09% below the current Price to Earnings Ratio (P/E).
Novo Nordisk A/S average Price to Earnings Ratio (P/E) for the last 52 weeks is 35.49.

Daily

From:

To:

Zoom:

Key data

Date	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)

Copenhagen Stock Exchange: NOVO-B.CO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 6, 2001
Location	Denmark
Headquarters	Novo Alle 1
Employees	77,406
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.